Small interfering RNA-based molecular therapy of cancers

Chinese Journal of Cancer

Volumn 32, Issue 9, 2013, Pages 488-493

  Guo, Wei ^a,b   Chen, Wangbing ^a   Yu, Wendan ^b   Huang, Wenlin ^a,c   Deng, Wuguo ^a,b,c  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c Guangzhou Double Bioproduct Inc   (China)

Author keywords

Cancer; Gene delivery; Molecular therapy; siRNA

Indexed keywords

ALN VSP 02; CARBON NANOTUBE; DENDRIMER; GOLD NANOPARTICLE; KINESIN; LIPID; POLO LIKE KINASE 1; POLYMER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

BREAST CANCER; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; CELL TRANSFORMATION; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFICACY; GENE FUNCTION; GENE IDENTIFICATION; GENE LIBRARY; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; LIVER CANCER; LOSS OF FUNCTION MUTATION; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; MELANOMA CELL; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE K RAS; OVARY CANCER; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; RNA INTERFERENCE; SOLID TUMOR;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG EVALUATION, PRECLINICAL; GENE TARGETING; GENETIC THERAPY; GOLD; HUMANS; NANOPARTICLES; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84874341556     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10280     Document Type: Review

References (39)

1. Xie W, Liang C, Birchler JA. Inhibition of RNA interference and modulation of transposable element expression by cell death in Drosophila. Genetics, 2011,188:823-834.
2. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21 nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001,411:494-498.
3. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 2004,432:173-178.
4. Jagani H, Rao JV, Palanimuthu VR, et al. A nanoformulation of siRNA and its role in cancer therapy: in vitro and in vivo evaluation. Cell Mol Biol Lett, 2013,18:120-136.
5. De Fougerolles A, Vornlocher HP, Maraganore J, et al. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov, 2007,6:443-453.
6. Ye OR, Zhang YC, Peng XQ, et al. Silencing Notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax. Oncol Lett, 2012,3:879-884.
7. Bai Z, Zhang Z, Qu X, et al. Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1. Oncol Lett, 2012, 3:35-140.
8. Radia AM, Yaser AM, Ma X, et al. Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines. Int J Mol Sci, 2013,11:7959-7978.
9. Sethi G, Pathak HB, Zhang H, et al. An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. PLoS One, 2012,7:e47086.
10. Ashrafi K, Chang FY, Watts JL, et al. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature, 2003, 421:268-272.
11. Nickles D, Falschlehner C, Metzig M, et al. A genome-wide RNA interference screen identifies caspase 4 as a factor required for tumor necrosis factor alpha signaling. Mol Cell Biol, 2012, 32:3372-3381.
12. Boyer AP, Collier TS, Vidavsky I, et al. Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers. Mol Cell Proteomics, 2013,12:180-193.
13. Morgan-Lappe S, Woods KW, Li Q, et al. RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. Oncogene, 2006,25:1340-1348.
14. Aza-Blanc P, Cooper CL, Wagner K, et al. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol Cell, 2003,12:627-637.
15. Mackeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol, 2005,7:591-600.
16. Futami T, Miyagishi M, Taira K. Identification of a network involved in thapsigargin-induced apoptosis using a library of small interfering RNA expression vectors. J Biol Chem, 2005,280:826-831.
17. Brummelkamp TR, Nijman SM, Dirac AM, et al. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature, 2003,424:797-801.
18. Colas AR, McKeithan WL, Cunningham TJ, et al. Whole-genome microRNA screening identifies let-7 and miR-18 as regulators of germ layer formation during early embryogenesis. Genes Dev, 2012,26:2567-2579.
19. Lee SK, Park EJ, Lee HS, et al. Genome-wide screen of human bromodomain-containing proteins identifies Cecr2 as a novel DNA damage response protein. Mol Cells, 2012,34:85-91.
20. Berns K, Hijmans EM, Mullenders J, et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature, 2004,428:431-437.
21. Paddison PJ, Silva JM, Conklin DS, et al. A resource for largescale RNA-interference-based screens in mammals. Nature, 2004, 428:427-431.
22. Kittler R, Putz G, Pelletier L, et al. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature, 2004,432:1036-1040.
23. Mackeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol, 2005,7:591-600.
24. Duan Z, Zhang J, Choy E, et al. Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation. Clin Cancer Res, 2012,18:4580-4588.
25. Rottmann S, Wang Y, Nasoff M, et al. A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc Natl Acad Sci U S A, 2005, 102:15195-15200.
26. Shen H, You J, Zhang G, et al. Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater, 2012,1:84-89.
27. Puvanakrishnan P, Park J, Chatterjee D, et al. In vivo tumor targeting of gold nanoparticles: effect of particle type and dosing strategy. Int J Nanomed, 2012,7:1251-1258.
28. Hirsch L R, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A, 2003, 100: 13549-13554.
29. Liu H, Liu T, Wu X, et al. Targeting gold nanoshells on silica nanorattles: a drug cocktail to fight breast tumors via a single irradiation with near-infrared laser light. Adv Mater, 2012,24:755-761.
30. O'Neal DP, Hirsch LR, Halas NJ, et al. Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett, 2004, 209:171-176.
31. Qu X, Yao C, Wang J, et al. Anti-CD30-targeted gold nanoparticles for photothermal therapy of L-428 Hodgkin's cell. Int J Nanomedicine, 2012,7:6095-6103
32. Sershen SR, Westcott SL, Halas NJ, et al. Temperature-sensitive polymer-nanoshell composites for photothermally modulated drug delivery. J Biomed Mater Res, 2000,51:293-298.
33. Conde J, Ambrosone A, Sanz V, et al. Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing. ACS Nano, 2012,6:8316-8324.
34. Zhao E, Zhao Z, Wang J, et al. Surface engineering of gold nanoparticles for in vitro siRNA delivery. Nanoscale, 2012,4:5102-5109.
35. Eibakry A, Zaky A, Liebl R, et al. Layer-by-layer assembled gold nanoparticles for siRNA delivery. Nano Lett, 2009,9:2059-2064.
36. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol.J, 2011,6:1130-1146.
37. Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet, 2011,12:329-340.
38. Koldehoff M, Steckel NK, Beelen DW, et al. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med,2007,7:47-55.
39. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticies. Nature, 2010,464:1067-1070.